EXANTA, AstraZeneca's new drug to prevent strokes, proved as effective as the standard therapy while offering advantages that could make it the new treatment of choice for millions of people with irregular heartbeats, researchers in the US have found.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in